Innovative Biologics Expected Biologic Drug Approvals in 2026 Big news for peptides! In July, the FDA will meet to evaluate the most commonly used peptides for FDA authorized compounding. A federal review is underway that could reclassify 14 peptides into FDA Category 1. This change that may influence how peptide therapies are accessed in the U.S. Here's what experts are FDA Decisions to Look For in 1H 2026 CGTlive FDA Peptide Reclassification 2026 Amanecia Health